Innovation has realized the potential of advanced therapies, but bioprocess and manufacturing tech advancements are now needed to feed future demand, says AltruBio’s Judy Chou.  While the COVID-19 pandemic kept industry physically apart – making the meet in San Diego this week the first BPI West since 2019 – it brought the biotech space together, resulting in the rapid approval and rollout of the first two mRNA vaccines. Concurrently, the past few years have seen numerous cell and gene therapy successes,…

Nutcracker Therapeutics has raised $167 million in Series C financing to expand its mRNA pipeline and refine its RNA platform. Nutcracker focuses on developing RNA therapeutics using its biochip-based manufacturing platform. The firm claims the financing, led by ARCH Venture Partners, will enable the company to grow its pipeline of messenger RNA (mRNA) medicines for cancer and advance its platform technology. According to Nutcracker, producing RNA-based therapeutics with scalability and speed has remained a constant challenge in the industry. To…